Latest News and Press Releases

The supplemental application for Toripalimab plus chemotherapy as perioperative treatment for resectable stage Ⅱ-Ⅲ NSCLC has been accepted by the NMPA.

Junshi Biosciences and Fosun Wanbang will cooperate on the development and commercialization of roconkibart in the Greater China Region.

NEOTORCH has finished its final analysis and met all the primary endpoints of EFS and MPR rate in the stage Ⅱ-Ⅲ NSCLC patients.

Junshi Biosciences announced its financial results for the full year of 2025 and provided corporate updates.

Jointly evaluate the synergistic therapeutic potential of JS207 (PD-1/VEGF BsAb) and ATG-037 (oral small-molecule CD73 inhibitor)

FDA has approved Junshi Biosciences' IND for a Phase 2/3 clinical study of JS207 (PD-1/VEGF), for the neoadjuvant treatment of NSCLC